Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
SAN DIEGO, Dec. 17 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc.
(Nasdaq: CADX ) today announced positive topline
results from Study 304, a
Phase III clinical trial of Acetavance(TM), the company's intravenous
formulation of acetaminophen, for the treatment of acute pain following
Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
SAN DIEGO, Jan. 11 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals,
Inc. (Nasdaq: CADX ) today announced top line results of two of the
company's four pivotal, Phase III clinical trials of Acetavance(TM), a
formulation of acetaminophen for intravenous use. One of these clinical
trials did n...
New Survey Reveals High Expectations for Popular Aesthetic Injections
...n Survey NewsWorthy Analysis. February--March 2009. Data on file, Medicis Pharmaceutical Corporation.
2. Kelton Research. Botulinum Toxin Survey topline
Report. February--March 2009. Data on file, Medicis Pharmaceutical Corporation.
Important Safety Information
Dysport (TM) is an acetylcho...
BioTrends Announces a New Syndicated Report Series, LaunchTrends(TM): Feraheme
...x months post launch. The first wave of the LaunchTrends(TM): Feraheme report series will be fielded in mid-August, measuring uptake at one month. topline
findings will be available shortly thereafter and the full report will follow in mid-September.
About BioTrends Research Group, Inc.
Hard Economic Times Affect Patients, Dentists - and the Tooth Fairy
Findings from a Survey of More Than 300 Dentists
30,000+ Dentists Conv...e of the largest displays of dental products in North America, here are the topline
findings from the survey:
Does the Tooth Fairy account for inflation?...
The State of the Tooth: Chicago-Area Residents Talk Dental
As we countdown to CDS's annual Midwinter Meeting, one of the largest displays of dental products in North America, here are some of the topline
findings from the survey.
On the economy's impact on their personal dental care:
One out of five Chicago-metro residents (22 p...
Following peanut product recall, six in ten Americans taking steps to reduce risk of sickness
The survey was conducted between February 4-8, 2009, during the peanut product recall that began on January 12, 2009.
Links to the survey topline
data and charts
"There's a striking level of awareness of this recall, and many people have taken action. But they're not aware of the range of pr...
Beckman Coulter Announces Third Quarter 2008 Results
...t continued, "I am encouraged by balanced, above-market revenue
growth across all major regions outside the U.S. and diagnostics product
areas. Robust topline
growth allowed us to invest in acquisitions of
promising new tests, our molecular diagnostics project and expansion of our
emerging markets' sales and...
Derma Sciences Announces Commercial Launch of XTRASORB(TM)
...dvanced wound care products, and then
to launch and support them with marketing and our growing sales
organization. This is what is going to drive our topline
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced
wound-care products. Its key prod...
Even before tomato warning, many Americans lacked confidence in the food safety system
...rking as well as it should," said Robert J. Blendon, professor of Health Policy and Political Analysis at the Harvard School of Public Health.
results and Powerpoint charts are available online.
Over a third of Americans (38%) worry about getting ill from the food they eat. Concern was gre...
Topline in Medical Technology
CV Therapeutics Announces Topline MERLIN TIMI-36 Results
- Full study results will be presented at the American College of
Cardiology's Scientific Session -
PALO ALTO, Calif., March 06, 2007 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. announced today that an analysis of unblinded
data from the MERLIN TIMI-36 study of ranolazine shows there was no
CombinatoRx Provides Topline Results from Phase 2 RA Study with
CRx-139 and Very Low Dose Prednisolone
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 26, 2007 - CombinatoRx,
Incorporated (NASDAQ: CRXX) today announced preliminary results of
a phase 2 clinical trial studying CRx-139 (a synergistic
combination of 3mg prednisolone and the antidepressant paroxetine)
and 3mg prednisolone alone, in patients with ...
deCODE Announces Positive Topline Results for Phase I Study of
DG051 for the Prevention of Heart Attack
REYKJAVIK, Iceland, May 01, 2007 /PRNewswire-FirstCall/ --
deCODE genetics today announced positive top-line results from its
Phase I multiple dose clinical trial of DG051, which the company is
developing for the prevention of heart attack. In the study, a
randomized, double-blind, multi- dose, as...
Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
CAMBRIDGE, Mass., Aug. 5 /PRNewswire/ -- Radius Health ("Radius") today announced topline
Phase 2 data demonstrating that in women with osteoporosis, BA058 -- the company's novel PTHrP (parathyroid hormone-related protein) analog -- signifi...
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
... reduction in steroid dose. We hope to have a full presentation of BLISS-52 results at an appropriate scientific meeting later in 2009."
BLISS-52 results include:
-- Based on an intention-to-treat (ITT) analysis, belimumab met its
primary efficacy endpoint of superiority v...
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
...were infrequent and all resolved with cessation of treatment."
Findings from ACHIEVE 1
Treatment Group Receiving Albinterferon Alfa...roup assigned to receive 900-mcg albinterferon alfa-2b every two weeks, the topline
results demonstrate that albinterferon alfa-2b met its primary efficacy end...
Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
...els with No Reversal of Analgesia
SAN CARLOS, Calif., March 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced positive topline
results today from a Phase 2 double-blind, randomized, placebo-controlled study of NKTR-118 in patients with opioid-induced constipation (OIC). NKTR-...
Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
...n the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive topline
results from a Phase 2 clinical trial with the intravenous form of its novel anionic quinolone antibiotic, delafloxacin (RX-3341). The double-blind st...
Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
...dominal laparoscopic surgery (Study 304). Although this trial is not
required as part of the Acetavance NDA, the company continues to expect to
results from Study 304 in the fourth quarter of 2008.
During the third quarter of 2008, and as previously announced, Cadence
also revised the expect...
VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Data from Phase 2 CEA and ACS Clinical Trials to be Released Concurrent with AHA Presentation
SAN FRANCISCO, Sept. 15 /PRNewswire...
Topline in Biological Technology